FMR1 and fragile X syndrome: Recently, an in silico transcriptome profiling of Fmr1-deficient mouse neurons highlighted the potential of the drug trifluoperazine (TFP) and revealed that TFP could normalize the elevated protein synthesis, which is a key defect in the FXS.